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Summary 
Pulmonary arterial Hypertension (PAH) is a progressive disease which is characterized 
by the elevated level of mean pulmonary arterial pressure. Increased pulmonary arterial 
pressure  is the consequence of vasoconstriction, pulmonary vascular remodelling and 
in-situ thrombosis of medium and small size arteries and arterioles (Humbert et al. 
2004). The term "vascular remodelling" describes structural changes of vasculature, in 
particular occlusions or hypertrophy. In normal conditions, there is a balance between 
proliferation and apoptosis of vascular cells, namely fibroblasts, endothelial cells or, 
the most relevant for our studies, pulmonary arterial smooth muscle cells (PASMCs). 
In pulmonary hypertension, the balance is disturbed in favor of proliferation.  
Janus Kinases, JAK1, JAK2, JAK3 and TYK2, are the family of tyrosine kinases, 
which mediate cytokine and growth factors signalling. The main downstream target of 
JAK is STAT, Signal transducers and activators of transcription, the transcription 
factors (Laurence 2012). After STAT is phosphorylated by JAK, it dimerizes and 
transclocates to the nucleus, where it interacts with the promoter regions of genes and 
regulates the transcription. 
Aberrant activation of the JAK/STAT pathway has been reported in a variety of disease 
states, including inflammatory conditions, hematologic malignancies, and solid tumors. 
A series of agents with different specificities against different members of the JAK 
family of proteins is currently undergoing evaluation in clinical trials for patients with 
myeloproliferative neoplasms (MPN), lymphoma, solid tumors such as breast or 
pancreatic cancer. 
STATs play an important role in cellular functions and it seems there are no exclusive 
upstream regulators. The cross-interaction between JAK, Src and STATs can explain 
the downregulation of phospho-STAT3 and STAT5 levels after inhibition of both Src 
and JAK, as well as comparable effects on PASMC proliferation and migration. It 
seems that Src and JAK act in concert with each other, maintaining the balance of 
common downstream targets. 
In our research we have confirmed the role of PDGF in regulating JAK and Src signal 
induction. Furthermore we have also demonstrated the interference of canonical 
JAK/STAT pathway with Src kinase and tight cooperation between JAK, Src and their 
downstream target STATs. More important, our study has demonstrated a positive 
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therapeutic effect of JAK1 and JAK2 inhibition by Momelotinib (CYT387). By 
comparing the result to another JAK inhibitor Pyridone 6 and Src inhibitor PP2, we 
conclude that targeting JAK decrease the proliferation and migration rates of human 
PASMCs, which is a therapeutic angle for PAH.  
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Zusammenfassung 
Die pulmonale arterielle Hypertonie (PAH) ist eine progressive Erkrankung, die durch 
den erhöhten mittleren pulmonal-arteriellen Druck charakterisiert ist. Ein erhöhter 
pulmonal-arterieller Druck ist die Folge von pulmonaler Vasokonstriktion, 
Remodelling der Lungengefäße und in-situ Thrombosen der mittleren und kleinen 
Arterien bzw. Arteriolen. Die Begriffe “Remodelling der Lungengefäße” beschreibt 
strukturelle Veränderungen der Gefäße. Unter normalen Bedingungen besteht ein 
Gleichgewicht zwischen Proliferation und Apoptosis der Gefäßzellen namens 
Fibroblasten, Endothelzellen oder glatte Gefäßmuskelzellen (PASMC). Von besonderer 
Relevanz in unserer Studie sind die PASMCs. Bei der pulmonalen arteriellen 
Hypertonie ist dieses Gleichgewicht zugunsten der Proliferation gestört. 
Janus Kinasen, JAK1, JAK2, JAK3 und TYK2, sind die Familien der Tyrosinkinasen, 
die die Zytokin- und Wachstumsfaktor-Signalwege vermitteln. Das hauptsächliche 
nachgeschaltete Zielprotein von JAK ist STAT (Signal transducers and activators of 
transcription). STAT sind die Transkriptionsfaktoren. Nach der Phosphorylierung von 
STAT durch JAK, kommt es zur Dimerisierung und Translokation in den Nukleus, wo 
es mit der Promotorregion der Gene interagiert und die Transkription reguliert. 
Fehlerhafte Aktivierung von JAK/STAT Signalwege wurden bei verschiedenen 
Erkrankungen dokumentiert, z.B. bei Entzündungen, malignen hämatologischen 
Erkrankungen sowie soliden Tumoren. Eine Serie von substanzen mit verschiedenen 
Spezifitäten gegen unterschiedliche Proteine der JAK Familie werden aktuell in 
klinischen Studien bei Patienten mit myeloproliferativen Neoplasien (MPN), 
Lymphomen sowie soliden Tumoren (z.B. Mammakarzinom, Pankreaskarzinom) 
evaluiert. 
STATs spielen eine wichtige Rolle in Zellfunktionen. Es wird vermutet, dass es keinen 
exklusiven vorgeschalteten Regulator gibt. Die gegenseitige Interaktion zwischen JAK, 
Src und STATs könnte sowohl die Runterregulation von Phospho-STAT3 und STAT5 
nach Inhibition von Src und JAK, als auch die vergleichbaren Effekte in der 
Proliferation und Migration von PASMC, erklären.  Es scheint, dass Src und JAK 
miteinander interagieren, um das Gleichgewicht von gemeinsamen nachgeschalteten 
Zielproteinen zu erhalten. 
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In dem vorliegenden Projekt konnten wir die Rolle von PDGF in der Regulation von 
JAK und Src Signalinduktion bestätigen. Weiterhin konnten wir die Interferenz 
zwischen dem kanonischen JAK/STAT Signalweg mit Src Kinasen sowie die enge 
Kooperation von JAK und Src mit den nachgeschalteten Zielproteinen STATs 
demonstrieren. Von Bedeutung ist, dass wir in unserem Projekt den positiven 
therapeutischen Effekt von JAK1- und JAK2-Inhibition durch Momelotinib (CYT387) 
zeigen konnten. Durch den Vergleich der Resultate mit denen eines anderen JAK 
Inhibitor namens Pyridone 6 und eines anderen Src Inhibitor namens PP2, 
schlußfolgern wir, dass die Steuerung von JAK zu einer Abnahme der Proliferation und 
Migration der humanen PASMCs führt und somit einen therapeutischen Aspekt für die 
PAH darstellt.  
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Abbreviations and Acronyms 
  
  ANOVA Analysis of variance 
ATP Adenosine triphosphate 
BMPR Bone Morphogenetic Protein Receptor 
BSA Bovine serum albumin 
BW Body weight 
CI Cardiac index 
CPMA Counts per minute average 
DAB 3,3' Diaminobenzidine 
DMEM Dulbecco's Modified Eagle Medium 
DMSO Dimethyl sulfoxide 
eNOS Endothelial nitric oxide synthase 
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NaOH Sodium hydroxide 
NO Nitric oxide 
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PDE Phosphodiesterase 
PDGF Platelet-derived growth factor 
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SAP Systemic arterial pressure 
SEM Standard error of the mean 
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SOCS Suppressor of Cytokine Signaling 
STAT Signal Transducer and Activator of Transcription 
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TCA Trichloroacetic acid 
TGF Transforming Growth Factor 
Thr Threonine 
TNF Tumor Necrosis Factor 
TPR Total pulmonary resistance 
TRK Tropomyosin-related kinases 
TSR Total systemic resistance 
UTP Uridine triphosphate 
VEGFR-2 Vascular endothelial growth factor receptor-2 
VIP Peroxidase Substrate kit 
VSMC Vascular smooth muscle cell 
vWF von Willebrand factor 
αSMA Alpha smooth muscle actin 
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1 Introduction 
1.1 Definition and Classification of Pulmonary Hypertension (PH) 
Pulmonary Arterial Hypertension (PAH) is a progressive disease which is characterized 
by the elevated level of mean pulmonary arterial pressure. To be more specific, the 
mean pulmonary arterial pressure (mPAP) has to exceed 25 mmHg at rest or 30 mgHg 
at excise (Groth et al. 2014; Kovacs et al. 2009) Left without treatment, the disease can 
lead to the failure of the right heart and consequent death.  
Pulmonary hypertension (PH) was first classified on an international WHO conference 
in 1973 and since then was subjected to many changes. Current classification was 
developed on the 5
th
 WHO conference in Nice 2013 (Table 1). According to the 
classification the term PAH is separated from PH due to left heart disease, PH due to 
lung diseases and/or hypoxia, chronic thromboembolic pulmonary hypertension 
(CTEPH), PH of miscellaneous etiologies, as shown in Table 1. (Simonneau et al. 
2013). 
1. Pulmonary arterial hypertension 
 1.1 Idiopathic PAH 
 1.2 Heritable PAH 
 1.2.1 BMPR2 
 1.2.2 ALK-1, ENG, SMAD9, CAV1, KCNK3 
 1.2.3 Unknown 
 1.3 Drug and toxin induced 
 1.4 Associated with: 
 1.4.1 Connective tissue disease 
 1.4.2 HIV infection 
 1.4.3 Portal hypertension 
 1.4.4 Congenital heart diseases 
 1.4.5 Schistosomiasis 
1′ Pulmonary veno-occlusive disease and/or pulmonary capillary hemangiomatosis 
1′′ Persistent pulmonary hypertension of the newborn (PPHN) 
2. Pulmonary hypertension due to left heart disease 
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 2.1 Left ventricular systolic dysfunction 
 2.2 Left ventricular diastolic dysfunction 
 2.3 Valvular disease 
 2.4 Congenital/acquired left heart inflow/outflow tract obstruction and congenital 
cardiomyopathies 
3. Pulmonary hypertension due to lung diseases and/or hypoxia 
 3.1 Chronic obstructive pulmonary disease 
 3.2 Interstitial lung disease 
 3.3 Other pulmonary diseases with mixed restrictive and obstructive pattern 
 3.4 Sleep-disordered breathing 
 3.5 Alveolar hypoventilation disorders 
 3.6 Chronic exposure to high altitude 
 3.7 Developmental lung diseases 
4. Chronic thromboembolic pulmonary hypertension (CTEPH) 
5. Pulmonary hypertension with unclear multifactorial mechanisms 
 5.1 Hematologic disorders: chronic hemolytic anemia, myeloproliferative disorders, 
splenectomy 
 5.2 Systemic disorders: sarcoidosis, pulmonary histiocytosis, 
lymphangioleiomyomatosis 
 5.3 Metabolic disorders: glycogen storage disease, Gaucher disease, thyroid disorders 
 5.4 Others: tumoral obstruction, fibrosing mediastinitis, chronic renal failure, 
segmental PH 
 
Table 1. Updated Classification of Pulmonary Hypertension on 5
th
 WHO PH 
conference in Nice-2013. BMPR = bone morphogenic protein receptor type II; CAV1 = 
caveolin-1; ENG = endoglin; HIV = human immunodeficiency virus; 
PAH = pulmonary arterial hypertension (Simonneau et al. 2013) 
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1.2 Pathophysiology of Pulmonary Arterial Hypertension 
Elevated pulmonary arterial pressure (PAP) is the consequence of vasoconstriction, 
pulmonary vascular remodelling and in-situ thrombosis of medium and small size 
arteries and arterioles (Humbert et al. 2004). In neonates and young children, PAH is 
associated with reduction of arterial number, muscularization of pulmonary 
vasculature. In older children and adults there is an additional hyperplasia, which 
results in occlusion processes in pulmonary arteries and plexiform lesions (Rabinovitch 
2008). Thickening of pulmonary arterial walls and muscularization of distal alveolar 
vessels can be explained by differentiation of pericytes into SMC, which then 
proliferate (B. Meyrick and Reid 1980). The thickening of the wall of more proximal 
pre-acinar and intra-acinar muscular arteries and destructive changes caused by 
neointimal formation were associated with excessive proliferation of SMC (Jones, 
Cowan, and Rabinovitch 1997). There might be subpopulations of SMCs or there are 
cell types which might originate from ECs (Frid, Kale, and Stenmark 2002) or 
fibrocytes  (Barbara Meyrick et al. 1974; Rabinovitch 2008) .  
1.2.1 Pulmonary vasoconstriction 
Vasoconstriction is defined as a reduction of blood vessel lumen. It is a primary factor 
of increased pulmonary vascular resistance (PVR) and high levels of mPAP (Mandegar 
et al. 2004). The regulation of vascular tone is maintained by the balance between 
vasodilators, such as nitric oxide (NO) or prostacyclin, and vasoconstrictors, such as 
thromboxane A2 or endothelin-1 (ET-1) (Budhiraja, Tuder, and Hassoun 2004). 
Endothelial dysfunction, due to inflammation or shear stress, is a primary cause of 
persistent vasoconstriction, by breaking this balance. PAH patients were found to have 
elevated levels of vasoconstrictors, like thromboxane, whereas prostacyclin levels were 
significantly reduced (Christman et al. 1992; J.a. et al. 2014). Another reason for PH is 
hypoxia mediated vasoconstriction, which is an adaptive mechanism in pulmonary 
circulation and often plays a major role in high attitude PH (Mandegar et al. 2004). 
 
1.2.2 In-Situ thrombosis 
In-situ thrombosis of pulmonary arterioles is one of the main histological 
representations of PAH (S. Rich 1998). Clotting cascade abnormalities, endothelial 
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dysfunctions, pro-coagulant environment, caused by platelet activation, are factors that 
could be responsible for this pathology (Humbert et al. 2004; Mandegar et al. 2004). In 
the plasma of IPAH patients, elevated levels of fibrinopeptide-1 and plasminogen 
activator inhibitor-1 (PAR-1) were found. Fibrinopeptide-1 is a fibrin generation 
marker and PAR-1 is responsible for fibrinolysis inhibition (Johnson, Granton, and 
Mehta 2006). Imbalance of vasoactive mediators is another reason for the thrombosis 
induction. An increase of thromboxane levels and decrease of prostaglandins and NO 
levels results in increased platelet aggregation, which consequently causes thrombosis 
of pulmonary vessels (Schermuly et al. 2011).  
1.2.3 Pulmonary vascular remodelling  
The term vascular remodelling describes the structural changes of the vasculature, 
including all vessel layers. In normal conditions, there is a balance between 
proliferation and apoptosis of vascular cells, like fibroblasts, endothelial cells or, the 
most relevant for our studies, pulmonary arterial smooth muscle cells (PASMCs). In 
pulmonary hypertension, the balance is disturbed in favor of proliferation. This leads to 
the pulmonary arterial wall thickening and occlusion of the vessel lumen, therefore 
increased PVR (Mandegar et al. 2004). In PAH all the three layers of the vasculature 
are involved in remodelling processes. These processes are characterized by adventitial 
proliferation, medial hypertrophy, intimal hyperplasia and plexiform lesions (Figure 1) 
(Dabral et al. 2012; Gaine and Rubin 1998).  
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Figure 1. Pulmonary vascular remodeling in the patients with pulmonary arterial 
hypertension (PAH). Pulmonary vascular pathology of patients with PAH is 
characterized by complex histopathological features, such as neointima formation (B, 
E; black arrows) and plexiform lesions (C, F; red arrows), compared to the healthy 
vessels (A, D). A, B, C: Elastica van Gieson staining; D, E, F: immunohistochemistry 
(α-smooth muscle actin (violet color) and von Willebrand factor (brown color)). Scale 
bars = 20 µm. (Kindly provided by my friend and labmate Dr. Djuro Kosanovic  from 
his dissertation (2011)). 
 
1.3 Molecular mechanisms of Pulmonary Arterial Hypertension 
The molecular mechanisms of PAH are still not clear, although the understanding has 
expanded significantly in recent years. Although the classification includes many 
different categories, there is a common pathway which results from a combination of 
environmental factors and genetic predispositions. During the last decade there is an 
increase of available treatments. The disease is characterized by an imbalance of 
vasodilators (prostacyclin, NO), vasoconstriction (endothelin-1) (Farber and Loscalzo 
2004), and vascular remodelling. All the processes mentioned above are having place 
during every entity of PAH. It is necessary to notice that modern medicine allows to 
regulate vasoconstriction and in situ thrombosis using specific vasodilators and oral 
anticoagulation. Average survival rates have improved significantly with the 
introduction of Phosphodiesterase-5 (PDE5) inhibitors and Endothelin Receptor (ERA) 
antagonists. However there are currently no efficient agents which could reverse the 
process of vascular remodelling and estimate of survival of 3,6 years still sounds 
discouraging (Anderson and Nawarskas 2010). Therefore the focus of pharmacological 
treatments has shifted from vasodilative approaches to anti-remodelling (anti-
proliferative and pro-apoptotic) approaches (Schermuly et al. 2011). 
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Figure 1. PAH is characterized by vasoconstriction, abnormal proliferation, 
inflammation hypoxia induced remodelling and dysregulation of vascular tone. 
Vascular lumen is significantly thickened due to smooth muscle cells proliferation. 
These processes lead to increased right ventricular afterload (Based on (Schermuly et 
al. 2011) 
 
During vascular remodelling smooth muscle cell proliferation, medial layer 
hypertrophy, muscularization of the artery and proliferation of endothelial cells can be 
observed.  Alterations in endothelial cells were noted to precede the muscularization of 
pulmonary artery (Rosenberg and Rabinovitch 1988) It was also shown that factors, 
released by EC, such as FGF2, induce proliferation of SMCs when added into the cell 
culture. (Thompson and Rabinovitch 1996)  There are multi-factors which might 
initiate vessel wall remodelling process. Bone Morphogenetic Protein Receptor type II 
(BMPR2) is predominantly expressed in smooth muscle cells and endothelium and 
plays pivotal role in regulation of the process of vascular remodelling in PAH. 
Mutations or alterations of BMPR2 seem to cause the vasculopathic lesions, which are 
observed 30% of familial and 70% of idiopathic PAH patients. However BMPR2 
receptor dysregulation can be found in other categories of PAH as well. Takahashi et 
al. has found significantly downregulated levels of BMPR2 in rodents which were 
exposed to hypoxia (Takahashi et al. 2006).The experiment was confirmed on MCT 
model (Morty et al. 2007). 
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According to the data available from animal experiments and clinical studies, the 
inflammation processes play a role in the development of PH (Schermuly et al. 2011). 
Analysis of patient lung samples demonstrate that mononuclear cells are frequently 
observed in plexiform lesions, which consist of Macrophages, T cells and less 
frequently B-cells (Ralph T Schermuly et al. 2011). A high percentage of PAH patients 
among inflammatory disease patients like thyroiditis (Thurnheer et al. 1997) or among 
patients with autoimmune disorders is a strong indicator that inflammatory processes 
play an important role in PAH pathogenesis. The studies have shown that there is a 
correlation between the degree of perivascular inflammation and vascular wall 
thickness as well as mean pulmonary arterial pressure (mPAP) (Stacher et al. 2012).   
Savai et al observed elevated amount of mast cells pulmonary arteries of IPAH lung 
tissue, as well as high density of monocytes, dendritic cells and macrophages in IPAH 
vascular lesions (Savai et al. 2012), which results in elevated levels of cytokines, 
eicosanoids, endothelins, and reactive oxygen species (Burke et al. 2009; Hall et al. 
2009) and subsequent vascular remodelling. Also, in the same work an accumulation of 
different types of T-cells in remodelled pulmonary vasculature was observed. A 
statement that impaired function of Treg cells can be among the reasons of local 
inflammation was made as one of the conclusions (Savai et al. 2012). 
1.3.1 Molecular mechanisms of pulmonary artery smooth muscle cells (PASMC) 
proliferation 
Although the mechanisms underlying each category of PAH are different, almost every 
category could be characterized by abnormal proliferation of vascular tissues in the 
distal pulmonary vessels (Schermuly et al. 2011). The right ventricular afterload is 
significantly increased because of cross-sectional lumen reduction in pulmonary artery 
(Humbert et al. 2004).  It is known that all three layers of pulmonary artery, intima 
media and adventitia, are excessively proliferating during PAH. But the most active 
layer is media. PASMC in media switch from passive to active proliferative and 
antiapoptotic phase. Molecular cascades regulating the switch are not fully understood, 
although several pathways seem to be clarified. 
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1.3.2 Growth factors 
Growth factors regulate many processes in the cell, including proliferation, migration, 
differentiation. There are many of them widely known, like fibroblast growth factor 
(FGF), platelet-derived growth factor (PDGF), vascular-endothelial growth factor 
(VEGF), epidermal growth factor (EGF) and many others (Figure 3). This class of 
molecules interacts with specific receptors which possess tyrosine kinase activity. 
Among the growth factor receptors, the PDGF specific receptors are most intensively 
investigated (Crosswhite and Sun 2010).  
 
 
Figure 3. Growth factors significantly attenuate progression of PAH, inducing survival 
of cells, motility and proliferation. The authors of the picture used following 
abbreviations: Akt, v-akt murine thymoma viral oncogene homolog;  FGF, fibroblast 
growth factor; GF, growth factor; JAK-2, Janus-activated kinase 2; PDGF, platelet-
derived growth factor; PI3K, phosphoinositide-3-kinase; PKB, protein kinase B; SOCS, 
suppressor of cytokine signaling; STAT, signal transducer and  activator of 
transcription. Picture was modified from  (Schermuly et al. 2011) 
 
1.3.2.1 Platelet Derived Growth Factor (PDGF)  
PDGF was discovered about 30 years ago and was proven to have a major role in 
embryonic development, cancerogenesis, cardiovascular regulation or vasculogenesis. 
 19 
 
There are four ligands of PDGF family known so far: A, B, C, D. The combination can 
form 5 isoforms, both homo-or heterodimeric. There are two types of PDGF receptors, 
α- or β- which have different affinity levels to PDGF dimers. (Grimminger and 
Schermuly 2010). At the moment of interaction with the ligand, an autophosphorylation 
of PDGF receptor occurs. The docking sites for signal transduction molecules, which 
contain SH2 domain are created (Grimminger and Schermuly 2010). After the 
activation of the receptors, the downstream signalling pathways like MAPK and early 
response genes are activated as well (Grotendorst et al. 1982; Ross et al. 1974).  
There was a hypothesis suggesting that mechanisms of cell proliferation induction in 
PAH have a lot in common with cancer mechanisms (Grimminger and Schermuly 
2010; Rai et al. 2008). The later research demonstrated that molecular mechanisms of 
tumor growth have a lot in common with the processes of vascular changes in PH 
(Ralph Theo Schermuly et al. 2005). PAH patients were found to have elevated levels 
of PDGF (Humbert et al. 1998). In animal models of PAH both PDGF and PDGFR 
levels were elevated as well (Balasubramaniam et al. 2003; Jankov et al. 2005). PDGF 
is a strong mitogen and chemoattractant for pulmonary arterial smooth muscle cells 
(Yu et al. 2003). 
After showing the role of PDGF in PAH pathogenesis, the researchers have suggested 
to inhibit PDGF in PAH patients. Schermuly et al has demonstrated the reversal of 
pulmonary hypertension in two different pulmonary hypertension animal models after 
introduction of Imatinib (Ralph Theo Schermuly et al. 2005). Imatinib is an inhibitor of 
tyrosine kinase activity, was initially used to treat chronic myelogenous leukaemia 
through the inhibition of proto-oncogene ABL kinase activity. Administration of 
Imatinib helped to improve the survival rates, cardiac output and right ventricular 
hypertrophy. Reversion of smooth muscle cell proliferation and neointima formation in 
PAH patients after Imatinib treatment was then reported by Ghofrani et al (Ghofrani, 
Seeger, and Grimminger 2005). Based on this and other reports, a randomized, 
placebo-controlled widescale clinical trial was initiated. In this trial Imatinib was 
introduced in parallel with ongoing usual treatment of PH. Imatinib in PH, a 
Randomized Efficacy Study, or shortly IMPRES, has demonstrated a significant 
improvement in PAH patients. However further observations revealed serious side 
effects and Imatinib was not approved for clinical use in PAH. 
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1.3.2.2 VEGF 
VEGF belongs to PDGF family and forms a subfamily of five members: placental 
growth factor and VEGF A, B, C, D. The VEGF family plays an important role in 
wound healing, embryogenic angiogenesis, vasculogenesis, endometrium regeneration 
(Clifford, Deacon, and Knox 2008). The role of VEGF in PAH remains unclear, 
however there are some reports of increased VEGF and VEGFR2 levels in plexiform 
lesions in PAH patients (Hassoun et al. 2009). Some authors suggest that VEGF might 
modulate vascular remodelling in hypoxia induced-PAH model, but in the MCT model 
the levels of VEGF are shown to be decreased (Partovian et al. 1998). Another study 
has demonstrated that VEGF levels in PASMC are regulated via TGFβ/NADPH 
oxidase pathway. This pathway can play a role in pulmonary vascular remodelling by 
upregulation of reactive oxygen species (ROS) production (Mata-Greenwood et al. 
2003, 2005). It was also found that IL-6 overexpression significantly upregulated 
VEGF levels which resulted in vasculature remodelling (Steiner et al. 2009). The 
remodelling was accompanied by ERK activation, upregulation of antiapoptotic 
proteins like Bcl-2, survivin and elevated c-myc production. 
1.3.3 Cytokines 
Cytokines are specified as a large group of signalling molecules, secreted by immune 
cells, which regulate hematopoiesis, inflammation, immunity and lots of other different 
biological processes. These mediator proteins interact in endocrine, autocrine and 
paracrine manner. Many authors highlight the role of cytokines as primary in the 
pathogenesis in PAH (Balabanian et al. 2002; Dorfmuller et al. 2002; Hassoun et al. 
2009; Price et al. 2012). Cytokines could be also used as biomarkers to diagnose PAH 
in patients.  
1.3.3.1 Transforming Growth Factor β (TGFβ) Family 
One of the most common reasons of PAH, as it was mentioned before, are the 
mutations in bone morphogenetic proteins (BMP), which belong to the superfamily of 
Transforming Growth Factors. Approximately 60% of familial and 30% of Idiopathic 
Pulmonary Hypertension cases are caused by these mutations (Deng et al. 2000; Lane 
et al. 2000). There are other evidences which demonstrate the involvement of other 
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BMP/TGFβ pathway genes into a development of PH (A Chaouat et al. 2004; 
Trembath et al. 2001).  
Bone morphogenetic protein receptor is a constitutively active serine/threonine kinase 
receptor which specifically binds to BMP2, BMP4, BMP7 and some other ligands. 
Activation of BMPR triggers signalling cascade via Smad1, Smad5 and Smad8. These 
cascades initiate the translocation of expression regulatory complexes into the nucleus 
(Humbert et al. 2004). Human pulmonary artery smooth muscle cells and pulmonary 
artery endothelial cells have BMP receptors on their surfaces. There is an evidence that 
MAP Kinases, including ERK, p38 and Janus Kinases are activated by BMPR and 
TGFβ receptors (Massagué and Chen 2000). It was also found that levels of BMPR2 
and BMPR1a are downregulated in PAH patients (Beppu et al. 2000; Du et al. 2003). 
TGFβ1 can also activate endothelin-1 production in PASMC via protein kinase a 
pathway (Markewitz et al. 2001) . In summary, we have to underline the importance of 
TGFβ role in regulation of growth and vascular tone, but the complexity of interactions 
and variety of the family keeps a lot of white spots. 
1.3.4 Molecular mechanisms of endothelial dysfunction 
Endothelial dysfunction is caused by imbalance between vasodilators and 
vasoconstrictors in the endothelium (Morrell et al. 2009). The levels of endogenous 
vasodilators are significantly downregulated in PAH patients. Expression of nitric 
oxide synthase (eNOS) is low, which negatively affects the levels of vasodilator NO. 
The levels of prostanoids are also downregulated. The administration of prostacyclin is 
one of the treatments which allows to reduce smooth muscle cells proliferation and 
improve pulmonary arterial pressure (Szczeklik et al. 1978). Elevated levels of 
thromboxane, serotonin, endothelin-1 and other vasoconstrictors were detected 
(Stewart et al. 1991). Serotonin (5-hydroxytryptamine, 5-HT) triggers abnormal 
endothelial-SMC crosstalk. The drugs that are attenuating the levels of 5-HT were 
shown to have an effect on PAH (Uchida et al. 2009). Mice which overexpress 5-HT 
show clear link between PAH and 5-HT levels (Eddahibi et al. 2006; Launay et al. 
2002). The process of endothelial dysfunction participates in vascular remodelling 
through activation of certain vasoconstrictors possessing proliferative properties and 
downregulation of vasodilators, which also stimulates cell proliferation (Ghamra and 
Dweik 2003; Ralph T Schermuly et al. 2011). As it was mentioned before, to treat 
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endothelial dysfunction in PAH, PDE5 inhibitors, prostacyclin analogues and 
endothelin receptor antagonists are used.  
Further vascular injury or shear stress can upregulate expression of vascular cell 
adhesion molecule-1 (VCAM-1), intracellular adhesion molecule-1 (ICAM-1), which 
may contribute to vascular wall remodelling by recruitment of monocytes and 
lymphocytes (Savoia et al. 2011). There are also various chemokines, which are 
upregulated in endothelium during PAH. Among them are Monocyte Chemotactic 
Protein-1 (MCP-1, also called CCL2) and Regulated on Activation, Normal T-cell 
expressed and secreted (RANTES, also called CCL5). Receptors were also shown to be 
upregulated (CX3CR1) (Balabanian et al. 2002; Crosswhite and Sun 2010). 
1.3.4.1 Endothelin-1 (ET-1) 
As it was mentioned before, deactivation of ETa and ETb  receptors is one of the 
treatment options of PAH. ET-1, depending on location of the cell, can bind one of the 
receptors and exert its mitogenic and/or vasoconstrictive effects. Interaction of ET-1 
with its receptor activates calcium channels, which coherently activates phospholypase-
C and the second messengers Ins(1,4,5)P3 and diacylglycerol, which results in 
vasoconstriction and cell proliferation (Bouallegue, Daou, and Srivastava 2007& 
Humbert 2004). After interaction with the ligand, ET receptor activates MAPK 
signalling cascade through GTPase, Ras, Raf, ERK. Phosphorylation of ERK activates 
MAPK and c-jun, which triggers proliferation processes (Bouallegue, Daou, and 
Srivastava 2007). 
1.3.4.2 Prostacyclin 
Prostacyclin is a pulmonary vasodilator, which mainly acts through cAMP-dependent 
pathways. Prostacyclin belongs to the class of eicosanoids, subclass of prostanoids. 
Besides prostacyclin, the subclass is formed also by prostaglandins and thromboxanes. 
Prostacyclin is secreted by endothelial cells, interacts with G-protein coupled receptor 
on SMC and activates adenylyl cyclase. Active adenylyl cyclase increases cAMP 
levels. cAMP activates protein kinase A, which downregulates myosin light chain 
kinase (MLCK) an results in relaxation of smooth muscle cells. Besides its vasodilating 
property, prostacyclin also suppress SMC proliferation through the interaction with 
surface prostanoid receptors. As a result of this interaction G-protein-coupled receptors 
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are active and cAMP level is elevated (Clapp et al. 2002). The antiproliferative 
properties of cAMP were found in different types of cell (Jourdan et al. 1999; Nilsson 
and Olsson 1984; Owen 1986). Prostacyclin has been intensively investigated and takes 
an important place in therapy of severe PAH. There are few FDA approved 
medications based on molecular therapeutic effect of prostacyclin available on the 
market. However, a clinical study has demonstrated that a chronic therapy with the 
prostacyclin analogue epoprostenol decreased mortality among patients with idiopathic 
IPAH, but could not prevent PASMC proliferation (Stuart Rich et al. 2010).  
1.3.4.3 Nitric Oxide (NO) 
NO is secreted by endothelial cells but the target is smooth muscle cell, where it 
possess vasodilatory effects, by upregulating the production of cGMP. cGMP is a 
second messenger, dephosphorylates myosin light chain which results in blood vessel 
dilation (Barst 2007). Another property of NO is the downregulation of smooth muscle 
cell proliferation through the ERK pathway (Zuckerbraun et al. 2007). Nitric Oxide 
was found to downregulate the activity of RhoA which results in antiproliferative effect 
(Zuckerbraun et al. 2007). 
1.3.5 Epigenetics 
Heritable phenotype characteristics or gene expression states that are encoded not by 
nucleotide sequences are explained by epigenetic modifications. Epigenetic 
modifications include DNA methylation, RNA interference or histone modifications. 
Histone modification and DNA methylation are the most important processes, which 
determine the regulation of cell growth, expression of apoptotic and proliferative genes. 
Epigenetic modification can be inherited or acquired according to the environment, but 
there is an evidence that it plays a role in pathogenesis of several diseases like asthma, 
cancer or even pulmonary hypertension (Kim et al. 2011; Xu, Cheng, and Du 2011).   
A disbalance in PASMC redox signalling due to tissue-specific epigenetic superoxide 
dismutase (SOD) deficiency results in heritable form of PAH (Archer et al. 2010). 
Attenuation of redox signalling creates anti-apoptotic and pro-proliferative conditions 
in cells. Downregulation of Kv1.5 channels and elevation of cytosolic calcium 
catalyzed PASMC proliferation, while increase of SOD levels reversed the process 
(Archer et al. 2010). The data provided by Xu et al. and Archer et al. clearly 
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demonstrate the evidence that epigenetic modifications can alter the pathogenesis of 
smooth muscle proliferation, endothelial dysfunction and apoptosis resistance, which 
play critical roles in pulmonary vascular remodelling.  
 It is a very well-known fact that noncoding conserved microRNAs - miRNAs, are 
important regulators of cellular processes and genes (Chan, Loscalzo, and White 2012; 
Parikh et al. 2012). These noncoding conserved microRNAs are involved in the process 
of cell survival, proliferation and differentiation. This brings us to the idea that 
miRNAs can play a role in pulmonary arterial remodelling. One of such miRNA, 
molecules which might be involved in pathogenesis of the disease could be miR21. The 
expression levels of miR21 are upregulated in lung vessel tissues of PAH patients and 
animal models (Parikh et al. 2012; Steiner et al. 2009). Moreover, miR21 was found to 
regulate pulmonary artery remodelling and hypoxia associated proliferation of 
PASMCs (Sarkar et al. 2010; S. Yang et al. 2012). The miR21 was found to be 
independently upregulated by BMPR2 and hypoxia in pulmonary arterial endothelial 
cells (Parikh et al. 2012). Deletion of miR21 upregulates the activity of Rho-kinase and 
enhances PA remodelling (Parikh et al. 2012). BMP induced cell growth is suppressed 
by miR21 and miR27. Loss of induction of these miRNAs results in excessive 
proliferation of PASMC.  Maybe  targeting miRNAs is another therapeutic option. 
1.3.6 Ion channels 
Besides the important function of promoting the cell contraction, calcium regulates 
gene expression and proliferation of smooth muscle cells (Landsberg and Yuan 2004). 
Calcium by interacting with calmodulin complex, stimulates the production of c-jun 
and c-fos, which activates mitosis in quiescent cells (Berridge 1993; Landsberg and 
Yuan 2004; X. R. Yang, Lin, and Sham 2010). Depending on different parameters, like 
duration, amplitude or frequency, the mitogen-induced calcium increase can activate 
different types of genes (Landsberg and Yuan 2004). As an example, PDGF via STAT3 
activates c-jun, which promotes the expression of transient receptor protein canonical 
genes (TRPC) (X. R. Yang, Lin, and Sham 2010), a voltage-independent cation 
channels (Landsberg and Yuan 2004). 
Voltage-gated potassium channels (Kv) are closed because of hypoxic pulmonary 
vasoconstriction and opened again because of following membrane depolarization. 
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PASMCs from PH patients demonstrated downregulation of Kv1.5 compared to 
healthy patients cells (Yuan et al. 1998).  
PASMC growth can be affected by mitochondrial potassium channels as well. 
Mitochondrial ATP-sensitive potassium channels (mitoKATP) depolarizes potential of 
mitochondrial membrane, which resulted in overproduction of hydrogen peroxide 
(H2O2) and inhibition of Cytochrome C release. Excessive H2O2 derived from 
mitochondria has anti-apoptotic and pro-proliferative effects by induction of AP-1 
family of early response genes, like c-myc, c-jun or egr-1(Huang et al. 1999).  The 
blocker of mitoKATP channel, 5-hydroxydeconoate (5-HD), increases cytochrome C 
release, which reverses the process: induces apoptosis and suppress proliferation. 
Introduction of 5-HD significantly reduced hydrogen peroxide levels and prevented 
excessive proliferation. 
 
1.4 Janus kinase/Signal Transducer and Activator of Transcription (JAK/STAT) 
pathway 
Janus Kinases, JAK1, JAK2, JAK3 and TYK2, are the family of tyrosine kinases, 
which mediate the cytokine and growth factors signalling. The main downstream target 
of JAK is STAT, Signal transducers and activators of transcription. STATs are the 
transcription factors (Laurence 2012). After STAT is phosphorylated by JAK, it is 
dimerized and transclocated to nucleus, where it interacts with the promoter regions of 
the genes and regulates the transcription (Figure 4) (Vahedi et al. 2012). STAT family 
consists of seven members: STAT1, 2, 3, 4, 5A, 5B and 6. Two different STATs can be 
activated by the same cytokine, but some of the interactions are fixed. It is known for 
example, that STAT1 an STAT2 are interferon signalling mediators, or IL2 activates 
STAT4 signalling pathway. STAT6 is involved in IL4, IL13 signalling mediating the 
IgE-dependent allergy response (Kaplan and Grusby 1998). STAT3 and STAT5 are 
involved in a broad spectrum is signalling cascades. It was shown that STAT3 or 
STAT5 deficient mice have the lethal phenotype (Leonard and O’Shea 1998).  
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Figure 4. Simplified view of JAK/STAT pathway. Upon cytokine or growth factor 
binding, JAK molecules are activated, which results in phosphorylation of downstream 
signalling cascade. STATs translocate to the nucleus and bind to promoter regions of 
genes involved in apoptosis and  proliferation (based on (Harrison 2012)) 
 
Janus kinases are very massive proteins, with molecular weight around 110-140 kDa. 
All the JAK family members have approximately the same structure. N-terminal FERM 
(a band four point one, ezrin, radixin, moesin) domain, an SH2 like domain, a JH2 like 
domain and a JH1 domain on C-terminus (Figure 5). Association of JAK with the 
receptor chain is regulated by FERM domain (Marko Pesu 2011). The role of SH2 
domain stays unclear. JH1 domain seems to be responsible for the kinase activity. The 
activation of JH1 domain seems to go through the transphosphorylation of the tandem 
tyrosines, which are located in the activation loop of the protein. This process might be 
mediated by receptor complex associated molecules of JAK. JH2, which is also called 
pseudo-kinase domain seems to perform the role of JH1 regulator and this role is still 
unclear. It was thought previously that JH2 domain in JAK2 has no catalytic activity. 
However recent publications have demonstrated that this JAK2 JH2 possess kinase 
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structure and phosphorylates Ser523 and Tyr570, which negatively regulates the 
activity of JH1 (Bandaranayake et al. 2012; Ungureanu et al. 2011). Mutations in JH2 
in  JAK3 resulted in loss of its function and severe combined immunodeficiency. That 
might mean that JH2 has also a positive regulatory role (Russell et al. 1995). Receptor 
complexes might interact with different JAK proteins. Erythropoietin receptor has two 
subunits which are identical too each other. Upon ligand binding they dimerize. 
Dimerized subunits bring together two JAK2 molecules, so close, that they 
transphosphorylate each other (Yoshimura and Misawa 1998). TYK2, because of 
interaction with mainly heteromeric receptors, interacts with JAK1 or JAK2 (Aittomäki 
and Pesu 2014; Yamaoka et al. 2004). 
 
 
Figure 5. Structure of JAK and the STAT3 isoforms. (A) The structural domains of 
JAK are referred to as JAK homology regions (JH1-JH7). JAK also possesses four 
functional domains: the FERM domain, the SH2 domain, the pseudotyrosine kinase 
(TK) domain and a catalytically active TK domain. B) Structure of the STAT3 
isoforms including the N-terminal coiled-coil domain, DNA binding domain, a linker, 
Src homology 2 (SH2) domain, and a C-terminal transactivation domain are shown, as 
well as the Tyr705 and Ser727 phosphorylation sites (Based on (S. W. Wang and Sun 
2014)). 
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1.4.1 Role of JAK/STAT pathway in human disease 
1.4.1.1 JAKs 
The importance of JAK-STAT in disease pathology has attracted a lot of attention in 
recent years. Inactivation of JAK1 (Rodig et al. 1998) or JAK2 (Neubauer et al. 1998) 
in mouse model results in lethal phenotype. Lack of JAK1 results in ill-defined 
neurological disorder. Lack of JAK2 leads to dysregulation in erythropoiesis. JAK3 and 
TYK knockout mice survive, but have immune system defects (Karaghiosoff et al. 
2000; Thomis et al. 1995). Mutations in JAK3 allele in human cause severe combined 
immunodeficiency (SCID) due to the lack of common gamma chain-family cytokine 
signalling. Patients with this kind of mutations have significantly lower number of NK 
and T-cells, dysregulation of B-cell functioning. However the reports about other 
pathologies were not presented (Macchi et al. 1995; Pesu et al. 2005). TYK2 mutations 
cause atopic dermatitis, increase IgE levels. All the findings mentioned above have 
resulted in idea of therapeutic inhibition of the JAK kinases.  
High activity of JAKs was found in myeloproliferative disease and cancers. V617 
mutation in JAK2 pseudokinase domain, for example, interrupts the autoinhibitory 
function and induces constant activation of JAK2 / STAT5 pathway and upregulated 
hematopoiesis (Pesu et al. 2005). Hyperreactivity mutations in all JAK family 
members, except TYK2 are associated with different types of leukemias and 
lymphomas (O’Shea, Holland, and Staudt 2013). In this sense, the inhibition of JAK 
seems to be logic. 
1.4.1.2 STATs 
There are data showing that STATs also have loss- or gain-of-function mutations. 
STAT1 or STAT5 gene silencing mutation causes interferon signalling and other types 
of cytokine signalling interruptions, which results in severe immunodeficiency (Uddin 
2003). STAT5B is also involved in signalling of growth hormones, so the loss-of-
function mutation causes the growth retardation (Kofoed et al. 2003). STAT3 was 
found to play important role in immunity against some types of bacteria and fungi: 
STAT3 gene silencing results in hyper IgE (Job's) syndrome, characterized by 
candidiasis, staphylococcal boils and high IgE level. Besides the problems with their 
immunity, another characteristics of STAT3 silencing are scoliosis and frequent 
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fractures (Milner et al. 2008; Siegel et al. 2011). Overexpression of STAT3 and STAT5 
results in Leukemias and lymphomas, similarly to JAK overexpression phenotypes 
(Koskela et al. 2012; O’Shea, Holland, and Staudt 2013; Rajala et al. 2013). Finally 
there is a link found between STAT genes regulatory region polymorphisms and 
immune diseases (Glosson, Bruns, and Kaplan 2012). It is important to mention that 
STATs do not have an enzymatic activity, like JAKs do. That is why it is much more 
difficult to target them therapeutically (Babon et al. 2014). However there are already 
dimerization inhibitors, siRNA STAT expression blockers and DNA binding inhibitory 
oligonucleotides which are developed and tested with variable success (B. X. Wang, 
Platanias, and Fish 2013). 
1.4.2 JAK  inhibition as therapy 
The concept of therapeutic JAK inhibition comes from two observations. First of all, 
JAK is involved in cytokine signalling regulation and the inhibition of JAK can result 
in immune suppression. In particular, interest was development of JAK3, mainly 
because the JAK3 deficient animals and patients with inactive JAK3 demonstrate the 
phenotype with alterations in immune system only (O’Shea et al. 2004). Also, the 
identification of JAK overexpression mutation carriers among patients with cancer and 
myeloproliferative disease resulted in the development of inhibitors. In 2014 there were 
only two JAK inhibitors which were approved by FDA for clinical use (Table 2) 
(Aittomäki and Pesu 2014). 
Ruxolitinib (INCB018424) is a JAK1 and JAK2 inhibitor which was approved by 
FDA in 2011 for the treatment of myelofibrosis and polycythaemia vera. It is approved 
in 36 countries for the clinical use. Ruxolitinib has no selectivity towards wild-type and 
mutant JAK2 and this is the main reason for side effects such as neutropenia and 
trombocytopenia, and more general, like nausea, fatigue or headache (Sonbol et al. 
2012). The adjustment of drug dosage alleviates leucopenia. Ruxolitinib efficacy was 
vindicated by several randomized, multi-centre placebo controlled clinical trials. 
Approximately half of the patients with myeloproliferative disease improved within 
first 3 month since the first drug administration. The indicator was significant reduction 
of the spleen size, higher survival rates and better systemic symptoms. Ruxolitinib was 
also studied in therapy of autoimmune diseases and the preliminary results demonstrate 
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efficiency and safety in phase IIa trial in rheumatoid arthritis patients (Quintas-
Cardama et al. 2011).  
Tofacitinib (CP690, 550, Xeljanz; Pfizer) was mainly developed as a JAK3 inhibitor. 
Initially was intended to suppress immunity in transplantations and autoimmune 
disease (Changelian et al. 2003). It was already mentioned that suppression of JAK3 
has minimum effects outside immune system, which was the advantage of JAK3 
inhibition. Later it was found that tofacitinib also inhibits JAK1 but has little effect on 
TYK2 an JAK2 function (Karaman et al. 2008; Meyer et al. 2010). The inhibition of 
JAK1 is also efficient due to its role in Interferon and IL6 signalling, main pro-
inflammatory cytokines (O’Shea et al. 2013). Tofacitinib was FDA approved for 
rheumatoid arthritis treatment in 2012. Although European Medicines Agency has 
declined Tofacitinib licensing. 
For our in vitro experiments we used different JAK inhibitors which are available on 
the market: 
Pyridone 6 (P6). It is a reversible and selective ATP-competitive JAK inhibitor with 
IC50 value of 1-15nM. Pyridone 6 is a pan JAK inhibitor. It inhibits the whole JAK 
family. P6 is also very selective, considering the experiments revealed no effects on 
other kinases (Nakagawa et al. 2011; Pedranzini et al. 2006) 
CYT387 (Momelotinib) is a selective ATP-competitive inhibitor of JAK1 and JAK2, 
with significant difference in activity compared with other kinases, developed by 
Gilead Sciences in 2013. Currently is in the phase I/II of clinical trials as a drug against 
myelofibrosis. 
New JAK inhibitors appearing on the market are mainly used to suppress immunity or 
to downregulate uncontrolled cell proliferation. Each of them has different levels of 
toxicity and number of side effects. It is also necessary to notice that there are currently 
no absolutely specific inhibitor on the market (Table 2) (Aittomäki and Pesu 2014). 
Taking into consideration the variety of inhibitors on the market and 
perspectives of manipulation with JAK STAT pathway to fight PAH, the 
following small research seems to be relevant.  
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Clinical trials of JAK inhibitors. 
Inhibitor JAKs affected Indication Phase 
Ruxolitinib JAK1, JAK2 Myelofibrosis FDA approved 
Polycythaemia vera FDA approved 
Acute leukaemia, 
lymphoma 
II 
Multiple myeloma I-II 
Essential 
thrombocythaemia 
II 
Prostate cancer II 
Breast cancer II 
Pancreatic cancer II 
Rheumatoid arthritis II 
INCB018424 
Phosphate cream 
JAK1, JAK2 Psoriasis II 
Tofacitinib JAK1, JAK3 Rheumatoid arthritis FDA approved 
Ulcerative colitis III 
Psoriasis III 
Renal transplantation II 
Juvenile idiopathic arthritis I 
Dry eyes II 
Lestaurtinib JAK2 Polycythaemia vera I/II 
Essential 
thrombocythaemia 
I/II 
Myelofibrosis I/II 
Multiple myeloma II 
Acute leukaemia, 
lymphoma 
II 
Neuroblastoma I 
Psoriasis II 
Baricitinib JAK1, JAK2 Rheumatoid arthritis II 
Psoriasis II 
Diabetic nephropathy II 
SB1518 (Pacritinib) JAK2 Myelofibrosis I/II 
Lymphoma I/II 
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CYT387 JAK1, JAK2 Myelofibrosis I/II 
SAR302503 JAK1, JAK2 Myelofibrosis I/II 
Polycythaemia vera, 
essential thrombocythaemia 
II 
Solid tumours I 
XL019 JAK1, JAK2 Myelofibrosis Discontinued (high 
Polycythaemia vera Rate of neurotoxicity) 
VX-509 JAK3 Rheumatoid arthritis II 
AZD1480 JAK1, JAK2 Myelofibrosis I/II 
Post-polycythaemia 
vera/essential 
thrombocythaemia 
I/II 
Solid tumours I 
INCB16562 JAK1, JAK2 Myelofibrosis Pre-clinical 
Multiple myeloma Pre-clinical 
NVP-BSK805 JAK2 Polycythaemia vera Pre-clinical 
GLPG0634 JAK1, JAK2, 
TYK2 
Rheumatoid arthritis II 
R-348 JAK3 Rheumatoid arthritis I 
Dry eyes I 
 
Table 2. Clinical trials of JAK inhibitors (Aittomäki and Pesu 2014) 
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2 Materials and methods 
2.1 Materials 
2.1.1 Chemicals, reagents, kits 
 
Company Product 
17-AAG inhibitor Selleck, USA 
17-DMAG inhibitor LC Laboratories, USA 
2-propanol Sigma- Aldrich, Germany 
Acetic acid Sigma- Aldrich, Germany 
Acrylamid Roth, Germany 
Ammonium persulfate (APS) Sigma- Aldrich, USA 
Ampicillin sodium salt Sigma, USA 
Bis(sulfosuccinimidyl)suberate (BS3) Thermo Scientific, USA  
Bleomycin Sigma-Aldrich, USA 
Bovine serum albumin powder Serva, Germany
Bovine serum albumin (2 mg/ml)  Bio-Rad, USA 
Bromophenol blue  Merck, Germany 
Cell proliferation ELISA, BrdU  Roche, USA 
Citric acid monohydrate  Sigma, Germany 
Collagenase type IV  Sigma-Aldrich, USA 
Crystal violet solution 2.3% w/v  Sigma-Aldrich, USA 
DAPI  Dakocytomation, USA 
DC™Protein Assay  Bio-Rad, USA 
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DEPC water  Roth, Germany
Disodium phosphate (Na2HPO4 x H2O)  Roth, Germany 
Dithiothreitol (DTT)  Sigma-Aldrich, USA
Dynabeads Protein G  Life Technologies, USA 
Enhanced chemiluminescence (ECL) kit Amersham, USA
Eosin-Y alcoholic Thermo Scientific, UK 
Ethanol 70%  SAV LP, Germany 
Ethanol 96% Otto Fischhar, Germany 
Ethanol 99.9% Berkel AHK, Germany 
Ethylenediaminetetraacetic acid (EDTA) Sigma-Aldrich, USA 
Formaldehyde 3.5-3.7%  Fischer, Germany 
Giemsa Merck, Germany
Glycerol Sigma-Aldrich, USA 
Hematoxilin Haemalaun nach Mayer Waldeck, Germany 
iScript cDNA synthesis kit Bio-Rad, USA 
Isoflurane  Baxter, UK
iTaqSYBR Green Supermix Bio-Rad, USA
LB agar  Invitrogen, USA 
Lipofectamine2000  Invitrogen, USA 
Luria Broth for medium  Invitrogen, USA 
May-Gruenwald  Merck, Germany 
Methanol  Sigma-Aldrich, USA 
MMPSense™ 680 Perkin Elmer, USA 
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Monopotassium phosphate (KH2PO4) Roth, Germany
Non-fat milk  Roth, German
Paraformaldehyde Sigma-Aldrich, USA 
Paraplast® Plus paraffin embedding 
medium  
Sigma-Aldrich, USA
Pertex® mounting medium  Medite, Germany
Picric acid solution 1.2%  AppliChem, Germany
Positively charged glass slides Langenbrinck, Germany 
Potassium chloride (KCl) Sigma-Aldrich, USA 
Precision Plus Protein Standards  Bio-Rad, USA 
RIPA buffer  Santa Cruz, USA 
S.O.C solution  Invitrogen, USA 
Saline (NaCl 0.9%)  B. Braun, Germany
SDS Solution, 10% w/v Promega, USA 
SIRCOL collagen assay  Biocolor Ltd., UK 
Sirius red F3B  Niepoetter,  Labortechnik
Sodium chloride (NaCl)  Sigma-Aldrich, USA  
Sodium citrate tribasic dehydrate  Sigma, Germany 
Tetramethylethylenediamine (TEMED)  Sigma-Aldrich, USA
TGF-β1 R&D System, USA 
Tissue-Tek® O.C.T™ Compound Sakura, Japan
Tris-HCl 0.5 M, pH 6.8  Amresco SOLON, USA  
Tris-HCl 1.5 M, pH 8.8  Amresco SOLON, USA  
Tris-HCl  Roth, Germany 
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Triton-X100  Sigma-Aldrich, USA 
TRIzol® Reagent  Life Technologies, USA
Trypsin 2.5%  Invitrogen, USA 
Tween®20  Sigma-Aldrich, USA 
UltraPure water Cayman Europe, Estonia 
Xylol (isomere) >98% pure, for histology  Roth, Germany
ZytoChem-Plus AP Kit, Broad Spectrum  Zytomed Systems
β-Mercaptoethanol Sigma-Aldrich, USA
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2.2 Methods 
2.2.1 Animal experiments 
Animals (mice and rats) were purchased from Charles River Laboratories 
(Sulzfeld, Germany). All the experiments were performed in accordance with the 
National Institute of Health Guidelines on the Use of Laboratory Animals. Study 
protocols (Nr. B2/191, Nr. 40/2009 and GI 2010-Nr. 03/2009 and Nr. 80/2009) were 
approved by both, the University Animal Care Committee and the Federal Authorities 
for Animal Research of the Regierungspräsidium Giessen (Hessen, Germany). 
 
Hypoxia+Su5416 induced PH rat model 
Su5416 (Semaxanib) was diluted in DMSO at a concentration of 25 µg/ml. Adult rats 
(200 - 250 g in body weight) were selected in a randomized manner and 
subcutaneously injected with Su5416 (20 mg/kg body weight) solution in the area of 
neck. Animals, immediately after the injection, were exposed to hypoxia (10% O2) in 
the ventilated hypoxia chamber. Control animals, which were injected with saline, were 
kept in normoxic conditions for the same time period. Hemodynamic studies and tissue 
freezing was made  after 3 weeks of hypoxia exposure. 
 
2.2.2 Cell culture 
All the cell culture experiments were performed in human pulmonary artery 
smooth muscle cells (hPASMCs) purchased from Lonza (Basel, Switzerland). 
hPASMCs from IPAH patients were isolated by explant method in our center. The 
study protocol for human tissue donation was approved by the Ethics Committee of the 
Justus-Liebig-University School of Medicine (No. 31/93) , and written informed 
consent was obtained from each individual patient.  
The media layer of distal pulmonary arteries were cutted into 1 mm 3 pieces 
after removal of pulmonary endothelium and adventitia. The artery pieces were planted 
on culture dishes in smooth muscle growth medium. Cells were maintained at 37˚C and 
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5% O2 in humidified chamber and cultured in the medium provided by Lonza 
(Clonetics™ SmGM™-2 Smooth Muscle Growth Medium-2). Cells were made to 
grow until 90-95% confluency and then were subcultured. For the procedure of  
subculturing, cells were washed twice with DPBS and incubated with Trypsin/EDTA 
for 2 min. Trypsin/EDTA was neutralized by addition of equal volume of FCS. Cells 
were centrifuged and then resuspended in a normal growth medium. After that cells 
were counted and seeded into new culture dishes. 
The procedure of cells freezing included following steps: after trypsinization, 
cells were resuspended in FCS which included 5% DMSO. Then the cells were 
aliquoted into 1ml cryovials, which were then frozen in isopropanol box at -80 ˚C. 
Following day, the tubes were transferred to a liquid nitrogen. During unfreezing, 
cryovials containing the cells were taken out quickly at 37 ˚C and seeded into a new 
culture dish. The following day, medium was changed to remove traces of DMSO. 
2.2.3 Cell Stimulation  
Inhibitors 
After reaching the confluency of  95% HPASMC cells were starved for 24 hours in 
Smooth Muscle Basal Medium (Lonza) before the stimulation. Stimulation of the cells 
was made in two stages. During first stage, the stimulus was added into the media. 1 hr 
later the inhibitors were added. After 30 min or 24 hours cells were washed with DPBS 
several times and collected for further procedures. The list of inhibitors used in 
experiments is reflected in  Table 3: 
Inhibitors Producers  
Momelotinib (CYT387) Abcam plc. United Kingdom 
PP2  Abcam plc. United Kingdom 
Pyridone 6 (P6) Merck Chemicals. Darmstadt. Germany 
Stattic (STT) Abcam plc. United Kingdom 
Table 3.  JAK/STAT inhibitors used in our experiments 
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2.2.4  Protein isolation 
2.2.4.1  Protein isolation from tissues 
Total protein was isolated in RIPA buffer (containing: 1x TBS, 1% Nonidet  P-40, 
0.1% SDS,  0.5% sodium deoxycholate, 0.004% sodium azide) as described in 
manufacturer’s instructions. Proteinase inhibitor cocktail, sodium orthovanadate and 
PMSF were prepared and added to RIPA freshly before use. 100 mg of lung tissue was 
homogenized in 600 μl RIPA or 2 × 106 hPASMC in 300 μl RIPA was centrifuged at 
12000 rpm for 30 min at 4 °C and the supernatant samples were kept at -80 °C. The 
protocol is demonstrated in Table 4 
Component of RIPA Final concentration 
RIPA buffer 1x 
Protease inhibitor cocktail 1x 
Sodium orthovanadate 1% 
PMSF 1% 
Table 4. RIPA buffer recipe 
2.2.4.2 Protein isolation from cells 
Protein isolation from primary hPASMCs was performed, using RIPA buffer 
(Thermo Scientific), which contains protease and phosphatase inhibitor cocktail 
(Thermo Scientific). Media was removed from the wells, which were then washed  with 
PBS. 75 µl of RIPA buffer was directly added to each plate and after 10 min of 
incubation at 4 °C. Cells were scratched from plates with cell scrapers and supernatants 
were transferred into 1.5ml tubes. The tubes were centrifuged for 30 min at 4 °C (13 
000 rpm). Supernatants were then transferred to clean 1.5 ml tubes. After that samples 
were quantified or stored at -80 °C. 
2.2.4.3 Protein estimation 
Protein quantification was performed using Bio-Rad DC Protein Assay kit. Bio-
Rad DC Protein Assay is a colorimetric assay, which is based on Lowry’s method 
involving reaction of protein with Folin reagent and an alkaline copper tartrate solution. 
This reaction gives a rise to a characteristic blue colour showing absorbance at 750 nm. 
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A set of different BSA concentrations in a range of 0.125 - 2 mg/ml was used as a 
standard. Protein samples were prediluted in a range of the standard and the 
measurement of absorbance was made at 750 nm using a TECAN microplate reader. 
Exact concentration values were calculated depending on the standards with reader 
accompanying Magellan™ software 
2.2.5 SDS polyacrylamide gel electrophoresis (SDS-PAGE) 
SDS PAGE is a method to separate various proteins in a sample according to their 
molecular mass for further immunoblot analysis. Protein samples from cells and tissues 
were equalized to similar concentrations and mixed with 5x gel loading buffer at a ratio 
of 4 : 1. After that, proteins were denatured at 95 °C for 10 min. Protein samples were 
loaded together with a molecular weight marker into the wells of 7% or 10% 
(depending on protein sizes to be separated) polyacrylamide gels. Gels were run in 
vertical electrophoretic assembly using 1x running buffer at 100 - 120 V for 2 - 3 hrs. 
Buffers used were made as written in Table 5: 
5×SDS gel-loading 
buffer component 
Final 
concentration 
Tris-HCl (2 M, pH 
6.8) 
375 mM 
SDS 10% (w/v) 
Glycerol 50% (v/v) 
β-Mercaptoethanol 12.5% (v/v) 
Bromophenol blue 0.02% (w/v) 
Table  5.  5×SDS gel-loading buffer recipe 
Polyacrylamide gels were prepared according to the following protocol. The space 
between two glass plates was filled with 8% - resolving gel solution. After that, 2- 
propanol was added on top of this mixture until the gels polymerized. After 30 min, 
resolving gel water was discarded and 6% - stacking gel mixture was added. A comb 
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was inserted and polymerization process took around 30 min. The protocols for running 
buffer and both SDS - PAGE gels are listed below in Tables 6, 7 and 8. 
Running buffer component Final concentration 
Tris-HCl 25 mM 
Glycine 192 mM 
SDS 10% (w/v) 0.1% (w/v) 
Table  6. Running buffer components 
 
Resolving gel (8%) component Volume 
Final 
concentration 
Tris-Cl (1.5 M, pH 8.9) 2.25 ml 375 mM 
Acrylamid 30% (w/v) 2.4 ml 10% (w/v) 
SDS 10% (w/v) 90 μl 0.1% (w/v) 
APS 10% (w/v) 45 μl 0.05% (w/v) 
TEMED 9 μl 0.1% (w/v) 
H2O 4.2 ml  
Table 7. Resolving gel (8%) components 
 
Stacking gel (6%) component Volume 
Final 
concentration 
Tris-Cl (0.5 M, pH 6.8) 0.625 ml 375 mM 
Acrylamid 30% (w/v) 0.5 ml 10% (w/v) 
SDS 10% (w/v) 25 μl 0.1% (w/v) 
APS 10% (w/v) 12.5 μl 0.05% (w/v) 
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TEMED 2.5 μl 0.1% 
H2O 1.34 ml  
Table 8. Stacking gel (6%) components 
2.2.6 Immunoblotting 
After proteins were separated on a gel, they were transferred to a nitrocellulose 
membrane by electrophoretic transfer. The blotting process takes 1 hr at 100 V in a 
transfer buffer. The protocol of blotting buffer is listed below. 
Blotting buffer Final concentration 
Tris-HCl 50 mM 
Glycine 40 mM 
Methanol 20% (v/v) 
Table 9. Blotting buffer 
 
After the transfer process, nitrocellulose membranes were kept in a blocking 
buffer for 1hr on a shaker at room temperature. Then membranes were incubated 
overnight in primary antibodies diluted in blocking buffer at 4 °C (Table 10). All the 
stocks were diluted in proportion 1/1000. The list of antibodies used is presented in 
Table 11. Following day, membranes have to be washed 3 times for 10 min with 1x 
TBST buffer and then incubated for 1 hour at room temperature in secondary HRP-
conjugated antibodies, which are also diluted in blocking buffer. After 1 hr incubation, 
membranes were washed 3 times for 10 min each in 1x TBST and incubated with ECL 
substrate (Thermo Scientific). After reaction with ECL substrate, membranes were put 
into the cassette with Photographic films to detect the signal. The time of exposure was 
determined on the basis of signal intensity. 
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TBST buffer ( pH 7.6) component Final concentration 
Tris-HCl 20 mM 
NaCl 150 mM 
Tween 0.1% (v/v) 
Table 10. TBST buffer (pH 7.6) protocol 
 
Antibodies   
JAK1 Cell Signalling. Danvers. USA 
JAK2 Cell Signalling. Danvers. USA 
phospho-JAK1 Cell Signalling. Danvers. USA 
phospho-JAK2 Cell Signalling. Danvers. USA 
beta-Actin Abcam plc. United Kingdom 
Stat3 Cell Signalling. Danvers. USA 
phospho-Stat3(Ser727) Cell Signalling. Danvers. USA 
phospho-Stat3(Tyr705) Cell Signalling. Danvers. USA 
Stat5 Cell Signalling. Danvers. USA 
phospho-Stat5(Tyr694) Cell Signalling. Danvers. USA 
Table 11. Antibodies 
Sometimes, In order to reuse the membranes and check the signal of 
housekeeping genes, membranes were stripped in a stripping buffer (Thermo Scientific) 
for 30 min at 37 °C, washed in TBST and incubated again with primary antibody. 
Densitometric analysis of the immunoblots 
Western blots were quantified using the densitometry software. Expression was 
quantified using bands intensity values (in arbitrary units), which were normalized to 
the housekeeping genes (GAPDH or β-actin). 
2.2.7 Immunohistochemistry 
4 μm thick sections were cut from paraffin embedded tissues of lungs. Sections 
were kept at 65 °C for 20 min, followed by removal of paraffin in xylene and 
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rehydration process in series of grade-decreasing ethanol solutions. Sections were 
washed thoroughly with PBS and boiled in 10 mM citrate buffer for 8  min at 630 watt 
in microwave for antigen retrieval. When needed, antigen retrieval was performed by 
using 0.25% trypsin for 10 min at 37 °C. After  treatment with 15% hydrogen peroxide 
for 20 min for blocking of endogenous peroxidases activity, NovaRED horseradish 
peroxidase (HRP)-substrate kit was used for immunohistochemical staining, in 
accordance with the manufacturer’s instructions. Samples were kept in serum blocking 
for 1 hr, followed by incubation overnight at 4 °C with primary antibodies. After 
washing with PBS solution, sections were kept with biotinylated secondary antibodies 
for 10 min, followed by a PBS wash again and incubation with streptavidin conjugated 
HRP for 5 min. After sections were washed, colour development was performed using 
a substrate/chromogen mixture, followed by counterstaining with haematoxylin. 
Sections stained were examined using microscope Leica DM 2500 and Leica QWin 
imaging software. 
 
2.2.8 BrdU incorporation assay 
Cellular proliferation for hPASMCs was determined using colorimetric BrdU 
incorporation assay kit (Roche) in accordance with manufacturer’s instructions. The kit 
is based on the idea of detecting Br-deoxycitidine incorporated into DNA, during DNA 
synthesis, by using anti-BrdU antibody conjugated with peroxidase enzyme. Rate of 
DNA synthesis is taken as a cellular proliferation marker. 
 
After a certain period of inhibitor treatment, cell culture is incubated with BrdU 
labelling substance for 6 hours. After the 6 hr incubation, cells are washed with PBS 
and subsequently fixed with FixDenat solution for 30 min. Fixed cells are then treated 
with anti-BrdU-POD antibody for 90 min, washed three times with PBS and further 
incubated with solution of substrate until colour development. Absorbance of samples 
is measured at 370 nm with reference at 492 nm in ELISA plate reader (TECAN). Cells 
proliferation is plotted as a function of absorbance at 370 nm. 
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2.2.9 Transwell assay 
The motility of human pulmonary artery smooth muscle cells with and without 
administration of different growth factors and inhibitors was estimated by transwell 
assay. During the assay, cells were placed on the upper layer of a cell permeable 
membrane and a solution containing the test agent is placed below the cell permeable 
membrane. Following an incubation period ( we had 6 hours), the cells that have 
migrated through the membrane are stained and counted. HPASMC cells were starved 
for 24 h before seeding 10 000 cells per well in the upper chamber of the transwell 
containing Smooth Muscle Basal Medium-2 (Lonza), where as the lower chambers 
contain three different subsets of SmBM medium, containing negative control (Pure 
SmBM), positive control (SmBM + 10% FCS) and combinations of stimulators and 
inhibitors 
.  
The transwell chamber was incubated at 37°C for 6 h to allow the migration of cells 
through the membrane into the lower chamber. Media was removed using a gentle 
suction. Cells were then washed with 1X PBS and fixed to the membrane using 
methanol wash for 2-3 min. After the fixation, cells were stained for 1-2 min with 
haematoxylin which gives purple colour to the cells. 
After the staining, the transwell was cleaned from inside with a cotton swab to remove 
the unmigrated cells and then we quantified the number of migrated cells that reached 
the lower part of the transwell filter membrane using a phase contrast microscope. 
 
2.3 Data analysis 
All data are expressed as mean ± SEM. The different experimental groups were 
analyzed by unpaired T-test. For multiple comparisons the different experimental 
groups were analyzed by one-way ANOVA and Newman-Keuls post-hoc test. Values 
of p<0.05 (*), p<0.01 (**) and p<0.001 (***) were considered as statistically 
significant. 
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3 Results 
3.1 Activation of JAK1 in human lung tissues of IPAH patients 
To investigate if the JAK expression and activation, western blots were performed on 
proteins from human PASMCs of IPAH and Donors. Cells were isolated by explant 
method in our center. The data demonstrated elevated levels of phospho-JAK1 in 
PASMCs from IPAH patients compared to the healthy Donors, which indicated the 
activation of JAK1 in IPAH (Figure 1). However, phospho-JAK2 was barely detectable. 
No Change of total JAK1 and JAK2 was observed.  
   A 
 
 
 
 
 
B 
 
Figure 1.PASMC from IPAH patients have slightly elevated levels of phospho-JAK 
compared to healthy donors, A) Levels of pJAK1, JAK1 and JAK2 were measured by 
western blots and quantified by densitometry. B) Densitometric quantification of 
signals using Beta-actin as a loading control. NTC means negative control. Values are 
expressed as mean ± SEM. n = 3. *P < 0.05, ***P < 0.001 vs NTC; #p < 0.05, ##p < 
0.01vs Donor 
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3.2 PDGF induced activation of STAT3 in hPASMCs can be blocked by JAK 
inhibition or SRC inhibition. 
To study the signaling pathway of JAKs, we utilized a pan-JAK inhibitor Pyridone 6 
(P6), a JAK1/JAK2 inhibitor Momelotinib (MLT) and Src inhibitor (PP2). Human 
PASMCs (hPASMCs) were stimulated with PDGF in the presence or absence of the 
inhibitors and the proteins were isolated and applied for western blot to study the 
pathways of JAKs. 
One of the downstream targets of JAKs is signal transducer and activator of 
transcription 3 (STAT3). There are two phosphorylation sites of STAT3, at tyrosine 
(Tyr) 705 and serine (Ser) 727 (Aittomäki and Pesu 2014). In both Donor and IPAH 
PASMCs, the phosphorylation of STAT3 at Tyr705 was significantly induced by 
PDGF or FCS, while Momelotinib blocked PDGF-induced phosphorylation of STAT3 
in a dose-dependent manner. We also observed a complete block of phosphorylation at 
Tyr705 after treatment with P6, a pan-JAK inhibitor, while Src kinase inhibitor PP2 
had much less effect (Figure 2A, B). However, the phosphorylation of STAT3 at 
Ser727 was induced in IPAH PASMCs but not in Donor PASMCs. Momelotinib and 
PP2 significantly reduced the phosphorylation at Ser727 in IPAH PASMCs, and P6 
treatment demonstrated a mild inhibitory effect (Figure 2B). 
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Figure 2. JAK and Src inhibition attenuates phosphorylation of STAT3 in hPASMCs. 
A) Phosphorylation of STAT3 at Tyr705 (Y705) and Ser727 (S727) in A) Donor 
PASMCs and B) IPAH PASMCs detected by western blots and quantified by 
densitometry using Beta-actin as a loading control. hPASMCs were stimulated with 
PDGF for 24 hours in the presence or absence of inhibitors: Momelotinib (MLT): 
JAK1/JAK2 inhibitor; Pyridone 6 (P6): pan-JAK inhibitor; PP2: Src inhibitor. NTC 
means negative control and FCS stimulation is used as a positive control. Values are 
expressed as mean ± SEM. n = 3.  *P < 0.05, **P < 0.01 vs NTC; # p < 0.05,  ## p < 
0.01, ### P  <  0.001 vs PDGF. 
 
3.3 PDGF induced activation of STAT5 in hPASMCs can be blocked by JAK 
inhibition or SRC inhibition 
Activation of STAT5 is signalled through the phosphorylation of Tyrosine (Tyr) 694. 
Western blot analysis demonstrated the activation of STAT5 after PDGF stimulation 
both in Donor and IPAH PASMCs, while FCS showed no effect on phosphorylation of 
STAT5. After the treatment with JAK inhibitor (Momelotinib and P6) or Src inhibitor 
(PP2), levels of phospho-STAT5 were significantly reduced  (Figure 3A, B). 
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Figure 3. JAK and Src inhibition attenuates phosphorylation of STAT5 in hPASMCs. 
A) Phosphorylation of STAT5 at Tyr694 (Y694) in A) Donor PASMCs and B) IPAH 
PASMCs detected by western blots and quantified by densitometry using Beta-actin as 
a loading control. hPASMCs were stimulated with PDGF for 24 hours in the presence 
or absence of inhibitors. Momelotinib (MLT): JAK1/JAK2 inhibitor; Pyridone 6 (P6): 
pan-JAK inhibitor; PP2: Src inhibitor. NTC means negative control. Values are 
expressed as mean ± SEM. n = 3. *P < 0.05, ***P < 0.001vs NTC; # p < 0.05, ## p <  
0.01 vs PDGF. 
 
 
3.4 JAK inhibition by pan-JAK inhibitor attenuates hPASMC proliferation. 
PASMC proliferation is most critical cellular feature for pulmonary vascular 
remodelling (Hassoun et al. 2009; Rabinovitch 2008). In our experiments we have 
demonstrated first that inhibition of JAKs by P6, a pan JAK inhibitor, suppressed 
hPASMC proliferation induced by FCS or PDGF in a dose-dependent manner. 
Moreover, P6 showed higher inhibitory efficacy on PDGF-induced proliferation as 
compared to FCS-induced proliferation (Figure 4). 
 
Figure 4. Pan-JAK inhibitor P6 inhibits hPASMC proliferation. Proliferation of Donor 
PASMC induced by A) FCS and B) PDGF. Cells were stimulated for 24 hours in the 
presence or absence of the pan-JAK inhibitor P6 for 24 hours with thymidine 
incorporation in the last 4 hours. Thymidine incorporation was shown average counts 
per minunte (CPMA) in treated cells relative to CPM in control. Values are expressed 
as mean ± SEM. n = 4; *** p < 0.001 vs NTC; # p < 0.05, ### p < 0.001 vs FCS or 
PDGF. 
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3.5 JAK1/2 inhibition by Momelotinib attenuates hPASMC proliferation. 
We also wanted to compare the effect of JAK1/2 inhibitor Momelotinib on 
proliferation of hPASMC from Donor and IPAH lungs. We have observed significant 
reduction of FCS induced or PDGF induced PASMC proliferation in both Donor and 
IPAH PASMCs by Momelotinib (Figure 5). However, PDGF stimulated proliferation 
of IPAH PASMCs are more sensitive to Momelotinib compared to Donor PASMCs 
(Figure 5 C,D), while no difference was observed in the case of FCS stimulated 
proliferation between Donor and IPAH PASMCs (Figure 5 A,B). P6 as well as higher 
dose of Momelotinib almost fully blocked hPASMC proliferation. Interestingly, 
inhibition of Src kinase by PP2 also fully blocked hPASMC  proliferation (Figure 5). 
 
Figure 5. JAK1/2 inhibitor Momelotinib inhibits hPASMC proliferation. A) 
Proliferation of  Donor PASMC and B) IPAH PASMCs induced by FCS, and 
proliferation of C) Donor PASMC and D) IPAH PASMCs induced by PDGF. Cells 
were stimulated for 24 hours in the presence or absence of the JAK1/2 inhibitor 
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Momelotinib (MLT) or Src inhibitor PP2 for 24 hours with BrdU incorporation in the 
last 4 hours. NTC means negative control. Values are expressed as mean ± SEM. n = 4; 
** p < 0.01,*** p < 0.001 vs  NTC; # p < 0.05, ### p < 0.001 vs FCS or PDGF. 
3.6 JAK inhibition and STAT3 inhibition decreases hPASMC migration. 
Increased ability to migrate of PASMCs is another important feature of pulmonary 
vascular remodelling (Hassoun et al. 2009; Rabinovitch 2008). To confirm the role of 
JAK-STAT pathway in cell migration, we performed Transwell assay on Donor 
hPASMCs with pan-JAK inhibitor Pyridone 6 (P6) and STAT3 inhibitor Stattic (STT). 
The data showed that both P6 and STT could inhibit FCS induced hPASMC migration 
(Figure 6). 
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Figure 6. JAK inhibitor P6 and STAT inhibitor Stattic decreases motility of hPASMC. 
A) Representative pictures of the transwell assay. B) Quantification of migrated 
PASMCs. Cells were stimulated with 5% FCS for 16 hours in the absence or presence 
of 1 μM P6 (pan-JAK inhibitor) or 2 μM STT (Stattic, STAT3 inhibitor). 
Magnification: 100X, Scale bar = 50 μm.  NTC means negative control. Values are 
expressed as mean  ±  SEM.  n  = 4; *** p < 0.001 vs  NTC; ### p < 0.001 vs FCS. 
 
3.7 JAK1/2 inhibition by Momelotinib decreases hPASMC migration. 
The transwell assay demonstrated that Momelotinib significantly decreased cell 
motility of hPASMCs after FCS stimulation as well as after PDGF stimulation to a 
similar extend. In addition, the inhibitory effect of Momelotinib is similar for IPAH 
PASMCs compared to Donor PASMCs, although the cell motility of IPAH PASMCs is 
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higher than Donor PASMCs in response to FCS or PDGF (3.5-fold & 2-fold vs 5 fold 
& 4-fold respectively) (Figure7). 
 
 
Figure 7. JAK1/2 inhibitor Momelotinib decreases motility of hPASMC. 
Representative pictures of the transwell assay and quantification of migrated A,B) 
Donor PASMCs; C,D) IPAH PASMCs. Cells were stimulated with 5% FCS or 25 
ng/ml PDGF for 16 hours in the absence or presence of 5 μM Momelotinib (MLT). 
Magnification: 100X. NTC means negative control. Values are expressed as mean ± 
SEM. n = 4; ***p<0.001 vs NTC; ###p<0.001 vs FCS or PDGF.  
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3.8 Levels of phosphorylated JAK1 are elevated in SuHox rat lungs. 
SuHox rat is a well-established animal model of PAH (Ciuclan et al. 2011). 
Immunohistostaining has demonstrated a moderate increase of JAK1 signal in SuHox 
rat lung tissues (Figure 9A, C). But the positive signal is not limited in pulmonary 
vessels. In contrast, signal of phosphor-JAK1 was concentrated in remodeled 
pulmonary arteries of SuHox rat lungs and significantly higher compared to healthy rat 
lungs (Figure 3B, C). 
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Figure 9. JAK1 activation in lung tissues of SuHox PH rats. Representative 
immunohistochemistry staining of A) JAK1 and B) phospho-JAK1 in paraffin lung 
sections from healthy and SuHox rats. Magnification: 400X, Scale bar = 20 μm. C) The 
total area of positive signal was quantified as Score Value. Values are expressed as 
mean ± SEM.  n = 5 for healthy and n = 6 for SuHox.  
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4 Discussion 
In the recent years, increasing evidence indicate a new paradigm that inflammation is a 
key pathological player in PAH (Cohen-Kaminsky et al. 2014; Schermuly et al. 2011). 
There were inflammatory infiltrates described in plexiform lesions, one of the main 
characteristic of PAH (Tuder and Voelkel 2015)  of lungs from IPAH patients. These 
infiltrates mainly consist of macrophages, T-lymphocytes and B-lymphocytes. 
However, it is not quite understood how inflammation initiates and/or promotes the 
pulmonary vascular remodelling in PAH. Different research groups have demonstrated  
substantial evidence that inflammatory cytokines play an important role in the 
development of PAH. PAH patients have increased circulating levels of tumor necrosis 
factor-α (TNFα), interleukins, Monocyte chemoattractant protein-1 (MCP1) etc 
(Humbert et al. 1995; Itoh et al. 2006).  
Soon et al indicated a significant dysregulation of inflammatory cytokine levels in 
IPAH patients (Soon et al. 2010). Consistent with the studies performed previously 
they observed significant upregulation of IL1β, IL6 and TNFα levels (Humbert et al. 
1995; Itoh et al. 2006). Also, levels of IL2, IL4, IL8 and IL10 were upregulated. .  
The recent publications suggest that IL-6 probably plays one of the most important 
roles in pathogenesis of PAH (Crosswhite and Sun 2010; Groth et al. 2014). According 
to clinical data, serum levels of IL-6 are significantly higher in PAH patients compared 
to controls (Humbert et al. 1995). The levels correlate with survival rates. It was also 
shown that IL-6 plays an important role in the development of PH in COPD. Plasma 
levels of IL-6 in COPD patients with PAH were higher than in those, without PAH. 
Moreover the levels of IL-6 were correlating with mean PAP (Ari Chaouat et al. 2009). 
Also there was a correlation between the presence of PAH and IL-6 gene 
polymorphisms in COPD patients: GG phenotype (-174G/C) of IL-6 gene determined 
higher mPAP than CC or GC phenotype (Ari Chaouat et al. 2009). These data 
demonstrate that variations in the genes of inflammatory cytokines may determine the 
development of PH. Approximately 6% of liver cirrhosis patients develop 
portopulmonary hypertension (PPHTN) (Kawut et al. 2008). There is a significant 
difference in IL-6 levels between patients with and without PAH as well. The 
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pathogenic role of cytokines was also demonstrated on animal PAH models (Miyata et 
al. 1995). Transgenic overexpression of IL-6 resulted in severe PH in mouse model 
(Steiner et al. 2009) and vice versa. IL-6 deficiency provides protection against 
hypoxia-induced PH progression (Savale et al. 2009). 
 Enhanced muscularization of main arteries and distal vessels was observed. Vascular 
tissues had occlusive neointimal angioproliferative lesions, mainly consisting of T-
lymphocytes and endothelial cells. These changes were correlating with right 
ventricular hypertrophy and systolic pressure of right ventricle (Savale et al. 2009; 
Steiner et al. 2009) 
Interestingly, a posttranscriptional mechanism which downregulates BMPR2 was 
suggested by Brock et al. It involves IL-6, microRNA cluster 17/92 and Signal 
Transducer and Activator of Transcription (STAT3) (Brock et al. 2009; Groth et al. 
2014). Functional levels of BMPR2 were restored after inhibition of these microRNAs 
by antagomiRs. The inhibition of microRNAs also downregulated IL-6 and particularly 
reverse vascular remodelling (Pullamsetti et al. 2012; Brock et al. 2012). 
IL-6 is also involved in other miR-independent pathways, which play a role in vascular 
remodelling. High levels of IL-6 induce upregulation of VEGFR2 and MMP9. Matrix 
metalloproteinase MMP9, is an endopeptidase which regulates the processes of cell 
migration, proliferation and cell attachment (Groth et al. 2014; Hiratsuka et al. 2002). 
Proliferation of PASMCs is activated by high IL-6 level (Groth et al. 2014). IL-6 
probably plays a role in the process of transformation of pulmonary endothelial into 
pulmonary smooth muscle cells (Steiner et al. 2009). 
PAH patients are found to have increased levels of IL-10, which seems to function as 
an inhibitor of inflammatory processes in lung tissues in a self-dense manner. IL-10 
treatment has significantly improved survival rates in MCT rats and stabilized mPAP in 
MCT rats (Ito et al. 2007). 
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IL-8 seems to play an important role in PAH development, in early stages of vascular 
remodelling. IL-8 act as a growth factor for endothelial cells and has antiapoptotic and 
proangiogenic properties (Li et al. 2005). These properties of IL-8 particularly explain 
elevated levels of IL-8 in PAH patients with connective tissue diseases. The fact that 
IL-8 levels are elevated in early stages of high altitude pulmonary edema suggests that 
this cytokine might play a role in response of pulmonary vasculature to hypoxic 
pressure (Kubo et al. 1998). 
In COPD patients without PAH the levels of TNFα were significantly lower than in 
those with PAH. Sutendra et al. suggested that elevated levels of TNFα can 
downregulate pyruvate dehydrogenase (PDH). PDH is a mitochondrial gate-keeping 
enzyme and might activate apoptosis resistance in PASMC. One of the evidence is the 
fact that TNFα treated cells demonstrated significantly lower PDH activity, while 
TNFα antagonist (Etanercept)-treated MCT rats had better resistance to PAH 
development (Sutendra et al. 2011). In another experiment rats were exposed to TNFα 
blocker (rhTNFRFc) and demonstrated an improvement in pulmonary inflammation, 
right ventricular hypertrophy and hemodynamics (Wang et al. 2013). Etanercept 
ameliorates endotoxemic-shock-induced PH in pigs (Mutschler et al. 2006). On the 
other hand, some publications do not confirm therapeutic effects of TNFα antagonist 
therapy (Chung et al. 2003; Groth et al. 2014; Henriques-Coelho et al. 2008) 
Such a wide spectrum of inflammatory cytokines initiates certain molecular pathways, 
which results in inflammation, tissue remodelling and other pathogenic processes. One 
of the pathways, initiated by the cytokines is the JAK signalling cascade (Cohen-
Kaminsky et al. 2014; Schermuly et al. 2011). So it is of great interest to investigate if 
JAKs are key mediators of pulmonary vascular remodelling in PAH. 
 
4.1 Janus Kinase 
Janus kinases are constitutively associated with specific cytokine receptors. Upon 
binding with ligands, the dimerization of receptors occurs. This event induces 
conformational changes of JAKs and initiates the enzymatic activity. Active JAKs 
phosphorylate multiple tyrosine residues on itself as well another receptors including 
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receptor tyrosine kinases (Robb 2007). That creates docking sites for molecules which 
contain SH2 domains, including STATs. There are evidence suggesting that an absence 
of JAK disables initiation of downstream signalling by cytokines (Ingley and Klinken 
2006). Previously it was demonstrated that deletion of JAK2 in vascular smooth muscle 
cells (VSMCs) suppresses VSMC proliferation and migration, and induces VSMC 
apoptosis. Therefore VSMC conditional knockout mice present less neointima 
formation and vascular fibrosis-induced by Angiotensin II (Kirabo et al. 2011). 
By using a JAK inhibitor AG490, Masri et al demonstrated a beneficial effect of the 
JAK inhibitor AG490 in reversing PAECs proliferation (Masri et al. 2007) , suggesting 
a potential role of JAK in PAH. However, studies from Paulin and her colleagues 
reported unchanged JAK2 expression and activation in IPAH PASMCs (Christmann et 
al. 2011; Courboulin et al. 2011) when compared to donor PASMCs. Instead, they 
demonstrated the pro-proliferative and anti-apoptotic phenotype of PASMCs from 
IPAH patients is Src/STAT3 dependent rather than JAK-dependent (Courboulin et al. 
2011; Paulin, Meloche, and Bonnet 2012). But they didn’t mention whether JAK1 
activation was regulated. 
In our study we observed that JAK1 and JAK2 are equally expressed in PASMCs from 
donors and IPAH patients on both mRNA and proteins levels. JAK1 
phosphorylation/activation is elevated in PASMCs from IPAH patients compared with 
donors, while JAK2 phosphorylation/activation were barely detectable in PASMCs 
(data not shown).  
In line with the findings from PASMCs, we also observed increased JAK1 activation in 
pulmonary vasculature of rats with SuHOX-induced PAH, which opens the opportunity 
to investigate theoretical effects of selective JAK inhibitor on an experimental animal 
model.   
4.2 Role of JAK signaling in PASMC proliferation 
PDGF-JAK-STAT signalling 
STAT3 has long been considered as one of the most predominant pro-survival 
mediator. For example numerous studies have shown STAT3 activation in different 
 62 
 
blood malignancies and solid tumours (Bowman et al. 2000). STAT3 is reported to 
control vascular remodelling in many studies. More relevantly, STAT3 is shown to be 
activated in PAH and inhibition of STAT3 results in less PASMC proliferation and 
pulmonary vascular remodelling ( Pullamsetti et al. 2012; Courboulin et al. 2011). 
Also, PASMCs express TRPC1, TRPC3, TRPC4 and TRPC6, which might play a role 
in proliferation. It was suggested that TRPC6 promotes agonist-induced calcium entry 
via STAT3/c-jun signalling pathway. The expression levels of TRPC6 were 
significantly elevated in lung tissues of PH patients (Inoue et al. 2001). Downregulation 
of TRPC6 activity decreased proliferation of PASMCs and resulted in vascular tone 
improvement (Yang, Lin, and Sham 2010; Slish, Welsh, and Brayden 2002). In 
summary, calcium signalling remains one of the attractive targets for further 
investigations.  
STAT3 is activated by numerous cytokines such as interleukins, and growth factors 
such as PDGF (Silvennoinen et al. 1993; Wagner et al. 1990). For example, PDGF was 
shown to constitutively activate STAT3 in cancer cells (Bowman et al. 2000). Given 
the significance of PDGF and PDGF receptors in PAH, PDGF initiated signalling 
pathways are of great importance. In accordance, our data presented increased STAT3 
phosphorylation along with JAK1 activation in PASMCs from IPAH patients compared 
to donors, suggesting a potential central role of JAK/STAT3 signalling cascade in 
PASMC proliferation.  
A recent study suggests that STAT3 and STAT5 are regulated independently. Activity 
of STAT5 was mainly dependent on Src, as the reactivation of JAK did not induce 
reactivation of STAT5. STAT3 activation was dependent mainly on JAK, because 
STAT3 was reactivated even after Src inhibition (Sen et al. 2009), as we observed in 
PASMCs as well. One explanation is suggested by Sen et al. that sustained Src 
inhibition results in inhibition of STAT5, which downregulates expression of SOCS2. 
Decreased SOCS2 levels are not capable to negatively regulate JAK2/STAT3 pathway, 
which results in increased JAK2 activity, JAK2-STAT3 interaction and STAT3 
activation (Sen et al. 2012). 
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In BCR-ABL1-expressing cells STAT5 was identified to be an important response 
modulator after treatment with TRK inhibitors. Decreased levels of STAT5 indicated 
high sensitivity of BCR-ABL1-positive cells to Imatinib (Warsch et al. 2011). Given 
our findings that JAK/STAT5 activation was blocked in PASMCs by JAK inhibitor, we 
may speculate that combination of Imatinib at lower dose with Momelotinib may 
exhibit a better efficacy against PAH with much less side effects of Imatinib. This 
aspect is intriguing and worth to investigate in the future. 
4.3  Src-STAT signalling 
Some reports state that activation of JAK does not result in activation of STAT, 
suggesting JAKs are the canonical upstream regulators of STAT3 and STAT5, but not 
the only ones (Smith, Metcalf, and Nicola 1997). Later there were some studies 
demonstrating the ability of SFK，another class of non-receptor tyrosine kinases, 
which are activated and constitutively associated with cytokine receptors and RTKs, 
Src family kinases (SFK), to phosphorylate STAT (Bowman et al. 2001; Kazansky and 
Rosen 2001; Okutani et al. 2001).  
SFKs seem to be the biggest group of non-receptor tyrosine kinases, consisting of nine 
members: Src, Yes, Blk, Lyn, Hck, Yrs, Fyn, Fgr, and Lck. All the family members 
have similar functions and structures (Parsons and Parsons 2004). SFK mediate 
mitogenic signalling from RTKs in many different ways.  Upregulation of Src kinase 
activity is also a signature of different types of cancer, including colon and breast 
carcinoma, various blood malignancies (Tice et al. 1999). PDGF was found to induce 
c-Myc expression and activate Src kinase (Kelly et al. 1983). It was shown that the 
activation of PDGF receptor results in transduction of a signal via Src kinase to 
STAT3, which is then translocated to the nucleus and activates the expression of pro-
proliferative and anti-apoptotic genes (Barone and Courtneidge 1995). 
Pullamseti et al have clearly demonstrated the central role of PDGF and various growth 
factors in activation of Src signalling in PASMC, both in vitro and in vivo (Pullamsetti 
et al. 2012). Our results are consistent with these findings, showing that inhibition of 
Src results in less STAT3 phosphorylation induced by PDGF. According to our 
observations, the cooperation between JAK and Src plays a crucial role in  PASMC 
proliferation. JAK/Src-dependent activation of STAT3 was also demonstrated after 
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AngiotensinII or ET1-dependent G-protein coupled receptor activation (Corre, 
Baumann, and Hermouet 1999; Marrero et al. 1998; Ram, Horvath, and Iyengar 2000). 
This could be particularly explained by direct signal-transduction from GPCR. Also a 
reciprocal cross-communication between RTK and GPCR could have place 
(Akekawatchai et al. 2005; Daub et al. 1996; Delcourt et al. 2007; Hobson et al. 2001; 
Mira et al. 2001; Shah and Catt 2004; Wetzker and Böhmer 2003). 
4.4 Role of PDGF-JAK-Src-STAT signalling in PASMC migration 
A very important feature of PASMC in PAH is a high capability to migrate. It was 
shown that PDGF induces migration of PASMC by activation of ERK/MAPK 
signalling pathway (Sarjeant et al. 2003; Yabkowitz et al. 1993; Yamboliev and 
Gerthoffer 2001). Also migration was induced through the activation of BMPR2 and 
receptor for advanced glycation end products (RAGE) (Lawrie et al. 2005; 
Spiekerkoetter et al. 2009). Tumor cell motility was suggested to be dependent on the 
balance between pro-invasive Src-STAT3 and opposite anti-invasive tumor suppressor 
p53. Our data confirm the importance of STAT3 in PASMC motility and demonstrate 
that targeting the upstream activators might give a positive therapeutic effect. 
STATs play too important role in cellular functions and it seems there are no exclusive 
upstream regulators. The cross-interaction between JAK, Src and STATs can explain 
the downregulation of phospho-STAT3 and STAT5 levels after both Src and JAK 
inhibitors, as well as comparable effects on PASMC proliferation and migration. It 
seems that Src and JAK act in concert with each other, maintaining the balance of 
common downstream targets. 
In summary, we have confirmed the role of PDGF in regulating JAK and Src signal 
induction. Furthermore we have also demonstrated the interference of canonical 
JAK/STAT pathway with Src kinase and tight cooperation between JAK, Src and their 
downstream target STATs. More important, our study has demonstrated a positive 
therapeutic effect of JAK1 and JAK2 inhibition by Momelotinib (CYT387). By 
comparing the result to another JAK inhibitor Pyridone 6 and Src inhibitor PP2, we 
conclude that targeting JAK decrease the proliferation and migration rates of human 
PASMCs, which is a therapeutic angle for PAH.  
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4.5 Limitations and perspectives 
There are limitations since our data were mostly based on in vitro experiments using 
different small molecular inhibitors. First, although the in vitro treatment of PASMC 
with inhibitors indicate that JAK/Src/STAT signaling is involved in PDGF-induced 
PASMC proliferation and migration, it is still not clear how those 3 key regulators are 
interacting with each other to control the phenotype of PASMCs during pulmonary 
vascular remodeling. A more complicated combination of inhibitors will give a better 
picture of the signaling mechanism. Second, due to the fact that JAK inhibitors are not 
selective between JAK1 and JAK2,  a genetic intervention such as siRNA knock-down 
would further confirm our the findings. Third, the potential of the JAK inhibitors as a 
treatment of PAH would be further strengthened with in vivo experiments by applying 
JAK inhibitor on the SuHOX-induced PAH animal model. 
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